Using risk stratification to assist in treatment selection was just one of the focal points at a recent presentation of the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Acute Myeloid Leukemia (AML) at the NCCN 15th Annual Conference. B. Douglas Smith, MD of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and a member of the NCCN Guidelines Panel for AML, spoke about the challenges in treating AML as well as recent updates to the NCCN Guidelines™. Dr…

Here is the original:
Risk Stratification Imperative To Treatment Selection In Patients With AML

You may also like:

• Patient Advocacy Group Asks FDA To Enhance Its Enforcement Of Unapproved Drugs Initiative
• Start Of Human Clinical Trial Of NIH-Developed Dengue Vaccine
• $29.4 Million Grant Establishes CTSI At NYU In Partnership With Health And Hospitals Corporation
• 2009/040 NICE Issues Final Guidance On The Use Of Cetuximab For The Treatment Of Head And Neck Cancer
• American Academy Of Ophthalmology’s Medical Director Of Health Policy Tapped For Role With National Quality Forum
• Hospitals In The News: ICU Deaths Higher On Weekend, Continuous Improvement Pays Off In Seattle
• Secretary Sebelius Visits Grand Isle Beach And New Orleans To Assess Health Impact Of Gulf Oil Spill
• New QUM Kit On Pain Management Available From PSA, Australia
• Minister Harney Welcomes Launch Of Health Funding Report, Ireland
• NICE Concerned Over Bone Cancer Drug’s Level Of Efficacy And High Cost In Draft Guidance